Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.

The global Swedish Porphyria Treatment market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Swedish Porphyria Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Swedish Porphyria Treatment market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Swedish Porphyria Treatment in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Swedish Porphyria Treatment manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Abbott
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
350mg
313mg

Segment by Application
Hospital
Pharmacy